These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29702856)

  • 1. A Cost-Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China.
    Wu Y; Zhou Q; Xuan J; Li M; Zelt S; Huang Y; Yin H; Huang M
    Value Health Reg Issues; 2013 May; 2(1):75-80. PubMed ID: 29702856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of amlodipine compared with valsartan in preventing stroke and myocardial infarction among hypertensive patients in Taiwan.
    Chan L; Chen CH; Hwang JJ; Yeh SJ; Shyu KG; Lin RT; Li YH; Liu LZ; Li JZ; Shau WY; Weng TC
    Int J Gen Med; 2016; 9():175-82. PubMed ID: 27330323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China.
    Ren M; Xuan D; Lu Y; Fu Y; Xuan J
    J Med Econ; 2020 Apr; 23(4):394-400. PubMed ID: 31782677
    [No Abstract]   [Full Text] [Related]  

  • 4. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
    Taylor M; Scuffham PA; Chaplin S; Papo NL
    Value Health; 2009 Jun; 12(4):459-65. PubMed ID: 19192258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
    Coyle D; Rodby RA
    Can J Cardiol; 2004 Jan; 20(1):71-9. PubMed ID: 14968145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
    Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of published economic evaluations of angiotensin receptor blockers.
    Theodoratou D; Maniadakis N; Fragoulakis V; Stamouli E
    Hellenic J Cardiol; 2009; 50(2):105-18. PubMed ID: 19329412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components.
    Stafylas P; Kourlaba G; Hatzikou M; Georgiopoulos D; Sarafidis P; Maniadakis N
    Cost Eff Resour Alloc; 2015; 13():10. PubMed ID: 26097434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Amlodipine in Stroke and Myocardial infarction: A Systematic Review and Meta-analysis.
    Iyengar SS; Mohan JC; Ray S; Rao MS; Khan MY; Patted URH; Gaurav K
    Cardiol Ther; 2021 Dec; 10(2):429-444. PubMed ID: 34480745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study.
    Saito I; Fujikawa K; Saruta T;
    Hypertens Res; 2008 Jul; 31(7):1399-405. PubMed ID: 18957811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
    Ferrario CM; Panjabi S; Buzinec P; Swindle JP
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.